OncoCyte (NYSE:OCX) Research Coverage Started at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of OncoCyte (NYSE:OCX – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.

OncoCyte Trading Up 3.0 %

Shares of OCX stock opened at $0.22 on Thursday. OncoCyte has a 1-year low of $0.20 and a 1-year high of $1.13.

Get OncoCyte alerts:

OncoCyte Company Profile

(Get Rating)

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.

Read More

• Get a free copy of the StockNews.com research report on OncoCyte (OCX)
• Game-Changing News For AMD And Its Shareholders
• How to Read Stock Charts for Beginners
• Can Chegg’s AI Pivot Save It From Disruption?
• Best Investment Strategy in 2023: Determine the Right One for You
• Enovix: A Rising Power in the Lithium-Ion Industry

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.